Zalicus Inc Com (NASDAQ:ZLCS)
CAPS Rating:
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
Recs
It was picked by www.hechtsoft.de Trade Alerts.